Review of drug development and therapeutic role of cholinesterase inhibitors in Alzheimer's disease

Drug Development Research

Volumn 56, Issue 3, 2002, Pages 347-353

  Sramek, John J ^a   Zarotsky, Victoria ^b   Cutler, Neal R ^a  

^a Ingenix Inc   (United States)

^b CALIFORNIA CLINICAL TRIALS   (United States)

Author keywords

Alzheimer's disease; Bridging studies; Cholinesterase inhibitors

Indexed keywords

ACETYLCHOLINE; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; PLACEBO; RIVASTIGMINE; XANOMELINE;

ABDOMINAL PAIN; ALZHEIMER DISEASE; ANOREXIA; BLOOD BRAIN BARRIER; CLINICAL TRIAL; DIARRHEA; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG TARGETING; DRUG TOLERABILITY; HEADACHE; HUMAN; MAXIMUM TOLERATED DOSE; NAUSEA; REVIEW; VERTIGO; VOMITING;

EID: 0036660258     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.10087     Document Type: Review

References (34)

1. Bodick N, Forette F, Hadler D, Harvey RJ, Leber P, McKeith IG, Riekkinen PJ, Rossor MN, Scheitens P, Shimohama S, Spiegel R, Tanaka S, Thal LJ, Urata Y, Whitehouse P, Wilcock G. 1997. Protocols to demonstrate slowing of Alzheimer disease progression. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alzheimer Dis Assoc Disord 11(Suppl 3):465-473.
2. Corey-Bloom J, Anand R, Veach J. 1998. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor in patients with mild to moderately severe Alzheimer's disease. Int J Geriat Psychopharmacol 1:55-65.
3. Cutler NR, Sramek JJ. 1995. Scientific and ethical concerns in clinical trials in Alzheimer's patients: the bridging study. Eur J Clin Pharmacol 48:421-428.
4. Cutler NR, Sramek JJ. 1998. Guidelines for conducting bridging studies in Alzheimer's disease. Alzheimer Dis Assoc Disord 12:88-92.
5. Cutler NR, Sramek JJ, Veroff AE. 1994. Alzheimer's Disease: Optimizing Drug Development Strategies. Chichester: John Wiley & Sons.
6. Cutler NR, Sramek JJ, Murphy MF. 1995. The use of bridging studies in drug development for Alzheimer's disease therapeutics. In: Cutler NR, Gottfries CG, Siegfriend K, editors. Alzheimer's disease: clinical and treatment perspectives. Chichester: John Wiley & Sons.
7. Cutler NR, Sramek JJ, Kilborn JR. 1996. The bridging concept: optimizing the dose for phase II/III in Alzheimer's disease. NeurodegenerationI 5:511-514.
8. Cutler NR, Anand R, Harman RD, et al. 1998a. Antiemetic therapy for Alzheimer's patients receiving cholinesterase inhibitor SDZ ENA 713. Clin Pharmacol Ther 63:513-521.
9. Cutler NR, Polinsky RJ, Sramek JJ, et al. 1998b. Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease. Acta Neurol Scand 97:244-250.
10. Doody RS, Geldmacher DS, Gordon B, et al. 2001. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol 58:427-433.
11. Feldman H, Gauthier S, Hecker J, et al. 2001. A 24-week, randomized, double-blind study for donepezil in moderate to severe Alzheimer's disease. Neurology 57:613-620.
12. Grutzendler J, Morris JC. 2001. Cholinesterase inhibitors for Alzheimer's disease. Drugs 61:41-52.
13. Kennedy JS, Polinsky RJ, Johnson B, et al. 1999. Preferential cerebrospinal fluid acetylcholinesterase inhibition by rivastigmine in humans. J Clin Psychopharmacol 19:513-521.
14. Meek PD, Mckeithan K, Schumock GT. 1998. Economic considerations in Alzheimer's disease. Pharmacotherapy 18:68-82.
15. Murphy MF, Siegfried KR. 1997. Cognition enhancers, agents, and pharmacodynamic models for Alzheimer's disease. In: Wolff ME, editor. Burger's Medicinal Chemistry and Drug Discovery, vol. 5, 5th ed. Chichester: John Wiley & Sons, p 95-120.
16. Murphy MF, Sramek JJ, Kurtz NM, et al. 1998. Optimizing the development of the next generation of compounds for Alzheimer's disease. London: Greenwich Medical Media Ltd.
17. Raskind MA, Peskind ER, Wessel T, Yuan W, et al. 2000. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 54:2261-2268.
18. Rogers SL, Doody TS, Mohs RC, et al. 1998a. Donepezil improves cognition and global function in Alzheimer's disease: a 15-week, double-blind, placebo-controlled study. Arch Intern Med 158:1021-1031.
19. Rogers SL, Farlow MR, Doody RS, et al. 1998b. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 50:136-145.
20. Rosler, M, Anand R, Cicin-Sain A, et al. 1999. Efficacy and safety of rivastigmine in patients Alzheimer's disease: international randomized controlled trial. BMJ 318:633-640.
21. Schrattenholz A, Pereira EFR, Roth U, Weber KH, et al. 1996. Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands. Mol Pharmacol 49:1-6.
22. Schumock GT. 1998. Economic considerations in the treatment and management of Alzheimer's disease. Am J Health Syst Pharm 55(Suppl 2):S17-21.
23. Selkoe DJ. 1992. Aging brain, aging mind. Sci Am 267:134-142.
24. Sramek JJ, Cutler NR. 2000. Ongoing trials in Alzheimer's disease. Exp Opin Invest Drugs 9:899-915.
25. Sramek JJ, Hurley DJ, Wardel TS, et al. 1995. The safety and tolerance of xanomeline tartrate in patients with Alzheimer's disease. J Clin Pharmacol 35:800-806.
26. Sramek JJ, Anand R, Wardle TS, et al. 1996. Safety/tolerability trial of SDZ ENA 713 in patients with probable Alzheimer's disease. Life Sci 58:1201-1207.
27. Sramek JJ, Frackiewicz EJ, Cutler NR. 2000. Review of the acetylcholinesterase inhibitor galanthamine. Expert Opin Investig Drugs 9:2393-2402.
28. Tariot P, Solommon PR, Morris JC, Kershaw P, et al. 2000. A 5 month, randomized, placebo-controlled trial of galantamine in AD. Neurology 54:2269-2276.
29. Taylor P. 1996. Anticholinesterase agents. In: Hardiman, JG, Limbird LE, Molinoff PB, Ruddon RW, editors. Goodman and Gilman's the pharmacological basis of therapeutics, 9th ed. New York: Mcgraw-Hill. p 161-176.
30. Taylor P. 1998. Development of acetylcholinesterase inhibitors in the therapy of Alzheimer's disease. Neurology 51(Suppl 1): S30-S35.
31. Thomsen T, Kewitz H. 1990. Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo. Life Sci 46:1553-1558.
32. Whitehouse PJ. 1997. Genesis of Alzheimer's disease. Neurology 48(Suppl 7):S2-S7.
33. Wilcock GK, Lilienfeld S, Gaens E. 2000. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomized controlled trial. BMJ 321:1445-1449.
34. Wilkinson D, Murray J. 2001. Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer's disease. Int J Geriat Psychiatry 16:852-857.